Literature DB >> 15078175

Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it.

Dean H Hamer1.   

Abstract

Stable remission is the ultimate goal of HIV therapy. A review of recent studies on the ability of HIV to persist despite highly active antiretroviral therapy (HAART) and immune stimulation suggests that achieving this goal will require four developments in basic and clinical science. First, more effective antiretroviral therapies, targeted at proteins other than reverse transcriptase and protease, in order to eliminate the cryptic replication that continues despite best available HAART. Second, agents that activate latent HIV gene expression in quiescent CD4 memory T cells, thereby exposing this viral reservoir to therapeutic intervention by a "shock and kill" strategy. Third, molecules such as immunotoxins that specifically recognize HIV-encoded membrane proteins and thereby potentiate the destruction of infected cells. Fourth, and still most distant, novel approaches such as genetically engineered cytotoxic T lymphocytes or anti-HIV microbes to suppress rekindling of infection by residual virus sequestered in anatomical and cellular reservoirs. Although each of these steps will be difficult to achieve, the many benefits of a cure for HIV make this a worthwhile pursuit.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078175     DOI: 10.2174/1570162043484915

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  49 in total

Review 1.  Immune-based therapies: an adjunct to antiretroviral treatment.

Authors:  Jeffrey M Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

2.  An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Authors:  Benjamin Trinité; Eric C Ohlson; Igor Voznesensky; Shashank P Rana; Chi N Chan; Saurabh Mahajan; Jason Alster; Sean A Burke; Dominik Wodarz; David N Levy
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

Review 3.  The multifaceted nature of HIV latency.

Authors:  Caroline Dufour; Pierre Gantner; Rémi Fromentin; Nicolas Chomont
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

4.  GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture.

Authors:  Anne Bruggemans; Gerlinde Vansant; Mini Balakrishnan; Michael L Mitchell; Ruby Cai; Frauke Christ; Zeger Debyser
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

5.  Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4+ T Cells following Latency Reversal.

Authors:  Jennifer M Zerbato; Gilda Tachedjian; Nicolas Sluis-Cremer
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

6.  Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.

Authors:  M A Rochat; E Schlaepfer; R F Speck
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

7.  Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Authors:  Amanda B Macedo; Camille L Novis; Caroline M De Assis; Eric S Sorensen; Paula Moszczynski; Szu-Han Huang; Yanqin Ren; Adam M Spivak; R Brad Jones; Vicente Planelles; Alberto Bosque
Journal:  JCI Insight       Date:  2018-10-04

8.  Lymphocytic choriomeningitis virus infection yields overlapping CD4+ and CD8+ T-cell responses.

Authors:  Courtney Dow; Carla Oseroff; Bjoern Peters; Courtney Nance-Sotelo; John Sidney; Michael Buchmeier; Alessandro Sette; Bianca R Mothé
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

9.  Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.

Authors:  Mark G Lewis; Sandro Norelli; Matt Collins; Maria Letizia Barreca; Nunzio Iraci; Barbara Chirullo; Jake Yalley-Ogunro; Jack Greenhouse; Fausto Titti; Enrico Garaci; Andrea Savarino
Journal:  Retrovirology       Date:  2010-03-16       Impact factor: 4.602

10.  Cell line-dependent variability in HIV activation employing DNMT inhibitors.

Authors:  Guerau Fernandez; Steven L Zeichner
Journal:  Virol J       Date:  2010-10-13       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.